Gleb von Anrep
The article by Dr Yentis (April 1998 JRSM, pp 209-12) filled a gap in my own task of writing the history of the development of sodium cromoglycate. Dr Yentis possibly underrates Anrep's work on khellin, stating that 'it had powerful vasodilator properties but did not fulfil its early promise of a useful therapeutic agent.' In a 1947 paper published in The Lancet (1947;i:558) , as well as reporting on the use of khellin in angina, Anrep describes its use as a bronchodilator in bronchial asthma. He states 'A complete and prolonged relief was obtained in 41 out of 45 cases after a single intramuscular injection of 200-300 mg. Complete relief is given 5-15 minutes after the injection and usually lasts about 24 hours. Repeated daily administrations of khellin by injection or by mouth conspicuously reduce the number and severity of the attacks.' Is this the first record of 'prophylaxis' or the use of a 'preventer' treatment in asthma?
In the early 1950s a British pharmaceutical company, Bengers Laboratories, based in Holmes Chapel in Cheshire, was selling an injectable formulation of khellin, Benecardin. Although primarily indicated as a vasodilator it was also used as a bronchodilator. In about 1953/1954 the research department at Bengers began a project with the objective of developing a soluble form of khellin that could be administered either orally or by inhalation as a bronchodilator. The initial animal screen they used was prevention of the fatal bronchoconstriction induced in guineapigs with inhaled histamine or methacholine. Later they used an anti-anaphylactic model guineapigs sensitized to egg albumin and rechallenged with inhaled egg antigen (the Herxheimer guineapig). Using this model they were able to show that some of the khellin derivatives they synthesized enhanced the protective effect afforded by antihistamines. This additional protective effect, which was shown if both the new compound and the antihistamine were administered before the antigen challenge, resulted from the ability of these compounds to inhibit the release of both histamine and the slow reacting substance of anaphylaxis (SRS-A) from the shocked guineapig lung.
In 1956 Dr Roger Altounyan became a medical liaison officer at Bengers Laboratories. Being asthmatic himself he joined this research team and being sceptical of the guineapig model began to challenge himself with inhaled antigen and to pretreat himself with the khellin derivatives. The first real evidence that khellin derivatives on their own would inhibit the bronchoconstriction induced by inhaled antigen came from a compound GR4 in 1957, but Altounyan and the research team set themselves strict criteria for the profile of the compound they wanted and it was not until 1965 that sodium cromoglycate (Intal) was discovered. But that is another story.
It was also through use of one of these khellin derivatives (FPL55712) that SRS-A was found to be several different chemicals, now called the leukotrienes.
Khellin is a chromone. Although one cannot be sure, it may well have been Anrep's Lancet paper that stimulated the research group at Bengers into seeking further chromones. This led to sodium cromoglycate and nedocromil sodium and indirectly to the newest group of antiasthmatic drugs, the antileukotrienes. Thus I can possibly correct Dr Yentis and suggest that Anrep's final work into the effects of khellin did lead to useful therapeutic agents.
Alan M Edwards 7 Fallowfield Close, Caversham, Reading RG4 8NQ, UK Hippocratism It was very satisfying to read in Professor Fabre's article (March 1998 JRSM, pp 161-163 ) that most of the Hippocratic tradition stems from the other treatises and not from the Oath itself, which in my view is largely a trades union charter for physicians. I was never able to reconcile the promise not to cut for the stone with the explicit and expert instructions, in a Hippocratic treatise, on how to trephine. It is possible that we should make a distinction between genitourinary surgeons and surgical neurologists. Obviously I should not have been so specialized in my reading, but as the university I attended never even mentioned the Oath I did not bother myself unduly. I recently discovered, greatly to my surprise, that a Scottish contemporary of mine had actually sworn it at his university.
J R W Gleave
Riversdale, Great Shelford, Cambridge CB2 5LW, UK Professor Fabre's article is much needed in these times when so many medical practices of an unethical nature are carried out. I take issue with the author in one important respect. He states, 'the blanket prohibition on euthanasia and abortion are not acceptable in today's society'. This is a true statement: however, this prohibition is now unacceptable for the sole reason that it conflicts with present-day practice, not because the prohibition is itself wrong. I do not consider that this precept should be omitted from a revised Oath for that reason. Because something is being done it does not automatically become morally correct. John Scotson 5 Woodville Road, Altrincham, Cheshire WA14 2AN, UK Technological medicine and the elderly Dr Mary Bliss (March 1998 JRSM, p 152) makes a valid point: modem hospitals have lost their compassion. Man is not a machine, and medical care is not a production line that can forever be speeded up. Older people are being discharged from hospitals too soon, inadequately prepared to cope with the vicissitudes of life in their own homes. Readmissions are rising and mismanagement abounds.
Student nurses have been taken off the wards to be educated in colleges, and too few nurses are available to nurse patients. Senior staff, apart from consultants, are rarely seen on the wards and decisions rain down from business managers seeking to meet targets by closing beds, downgrading staff, and forcing up throughput.
Ministers too have abdicated their responsibilities. The beauty of 'market forces' is that the concept enables ministers to avoid personal responsibility for the parlous state of affairs in our hospitals.
